Syros Pharmaceuticals Inc SYRS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SYRS is a good fit for your portfolio.
News
-
Syros Gets FDA Fast-Track Designation for Tamibarotene
-
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
-
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
-
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
-
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
-
Syros to Participate in TD Cowen 44th Annual Health Care Conference
-
Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin?
Trading Information
- Previous Close Price
- $5.14
- Day Range
- $5.00–5.20
- 52-Week Range
- $2.09–8.17
- Bid/Ask
- $5.06 / $5.07
- Market Cap
- $134.12 Mil
- Volume/Avg
- 89,636 / 214,076
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- https://www.syros.com
Comparables
Valuation
|
Metric
|
SYRS
|
CRNX
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.16 | 5.59 | 0.39 |
Price/Sales | 14.65 | 639.90 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SYRS
CRNX
PMVP
Financial Strength
|
Metric
|
SYRS
|
CRNX
|
PMVP
|
|---|---|---|---|
Quick Ratio | 3.80 | 12.92 | 14.47 |
Current Ratio | 3.95 | 13.07 | 14.78 |
Interest Coverage | −32.43 | — | — |
Quick Ratio
SYRS
CRNX
PMVP
Profitability
|
Metric
|
SYRS
|
CRNX
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −60.13% | −38.81% | −23.12% |
Return on Equity (Normalized) | −157.84% | −44.79% | −25.57% |
Return on Invested Capital (Normalized) | −85.62% | −45.62% | −27.79% |
Return on Assets
SYRS
CRNX
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hlpmfxpqm | Hnrr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lcgknhkw | Hdytflr | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Grhlvlfzq | Jbrqjxt | $99.6 Bil | |
MRNA
| Moderna Inc | Pmzgwzyk | Rhblq | $38.8 Bil | |
ARGX
| argenx SE ADR | Vbsqwplv | Pdl | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Qfckczfr | Svd | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lpryhhtm | Mcjwdl | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Djdlsnxlv | Bbnjcw | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mmnypzcjs | Kcsrfh | $12.4 Bil | |
INCY
| Incyte Corp | Lyylzjsl | Wnkcnj | $11.9 Bil |